Alimera Completes Recruitment for the Synchronicity Study
January 04, 2024 08:00 ET
|
Alimera Sciences, Inc.
ATLANTA, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners...
Alimera Acquires U.S. Commercial Rights to YUTIQ®
May 18, 2023 07:00 ET
|
Alimera Sciences, Inc.
Expected to be immediately accretive to revenue and Adjusted EBITDA in 2023 Alimera projects at least $100 million of consolidated net revenue and over $20 million of Adjusted EBITDA* in 2024...